FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1759346585> ?p ?o ?g. }

• W1759346585 endingPage "875" @default.
• W1759346585 startingPage "869" @default.
• W1759346585 abstract "Objectives To investigate whether using hydroxyethyl starch (HES) 130/0.4 as a pump prime and for intraoperative fluid therapy is associated with postoperative acute kidney injury (AKI) after adult cardiac surgery. Design Retrospective observational study. Setting University hospital, single center. Participants Six hundred six adult patients who underwent on-pump cardiac surgery between April 2013 and June 2014 were included. Interventions Until July 2013, balanced HES 130/0.4 (Volulyte®, Fresenius Kabi AG, Bad Homburg, Germany) was used both as a pump prime (1,500 mL) and for intraoperative fluid therapy (1,000 mL). From August 2013, HES was replaced entirely by a balanced crystalloid solution (Plasma-Lyte A, Baxter, Lessines, Belgium). Measurements and Main Results The primary endpoint was the incidence of postoperative AKI during the first 48 postoperative hours, determined using the Acute Kidney Injury Network classification. Secondary outcomes included kidney function at postoperative day 7, postoperative dialysis or hemofiltration, postoperative pulmonary complications, lengths of intensive care unit and hospital stays, postoperative fluid balance and urinary output, surgical revision for bleeding, and 30-day mortality. Multivariable logistic regression was used to adjust for confounders. AKI occurred in 9.5% of crystalloid patients and in 21.5% of HES patients. Patients who received HES were about twice as likely to develop postoperative AKI as those treated with crystalloids (adjusted OR 2.26; 95% CI, 1.40-3.80; p = 0.02). HES patients also had a significantly more positive fluid balance and a lower urinary output during the first 48 postoperative hours. The incidence of surgical revision for bleeding was greater in the HES group (4.6% v 1.4%, p = 0.02). Conclusion This study suggested that using balanced HES 130/0.4 as a pump prime and for intraoperative fluid therapy in adult patients undergoing on-pump cardiac surgery was associated with a greater incidence of AKI during the early postoperative period. To investigate whether using hydroxyethyl starch (HES) 130/0.4 as a pump prime and for intraoperative fluid therapy is associated with postoperative acute kidney injury (AKI) after adult cardiac surgery. Retrospective observational study. University hospital, single center. Six hundred six adult patients who underwent on-pump cardiac surgery between April 2013 and June 2014 were included. Until July 2013, balanced HES 130/0.4 (Volulyte®, Fresenius Kabi AG, Bad Homburg, Germany) was used both as a pump prime (1,500 mL) and for intraoperative fluid therapy (1,000 mL). From August 2013, HES was replaced entirely by a balanced crystalloid solution (Plasma-Lyte A, Baxter, Lessines, Belgium). The primary endpoint was the incidence of postoperative AKI during the first 48 postoperative hours, determined using the Acute Kidney Injury Network classification. Secondary outcomes included kidney function at postoperative day 7, postoperative dialysis or hemofiltration, postoperative pulmonary complications, lengths of intensive care unit and hospital stays, postoperative fluid balance and urinary output, surgical revision for bleeding, and 30-day mortality. Multivariable logistic regression was used to adjust for confounders. AKI occurred in 9.5% of crystalloid patients and in 21.5% of HES patients. Patients who received HES were about twice as likely to develop postoperative AKI as those treated with crystalloids (adjusted OR 2.26; 95% CI, 1.40-3.80; p = 0.02). HES patients also had a significantly more positive fluid balance and a lower urinary output during the first 48 postoperative hours. The incidence of surgical revision for bleeding was greater in the HES group (4.6% v 1.4%, p = 0.02). This study suggested that using balanced HES 130/0.4 as a pump prime and for intraoperative fluid therapy in adult patients undergoing on-pump cardiac surgery was associated with a greater incidence of AKI during the early postoperative period." @default.
• W1759346585 created "2016-06-24" @default.
• W1759346585 creator A5008880626 @default.
• W1759346585 creator A5010118602 @default.
• W1759346585 creator A5024195170 @default.
• W1759346585 creator A5026359213 @default.
• W1759346585 creator A5041838652 @default.
• W1759346585 creator A5045866570 @default.
• W1759346585 creator A5066614622 @default.
• W1759346585 creator A5079047956 @default.
• W1759346585 date "2016-08-01" @default.
• W1759346585 modified "2023-09-26" @default.
• W1759346585 title "Hydroxyethyl Starch 130/0.4 and the Risk of Acute Kidney Injury After Cardiopulmonary Bypass: A Single-Center Retrospective Study" @default.
• W1759346585 cites W1596318799 @default.
• W1759346585 cites W1966571627 @default.
• W1759346585 cites W1967300023 @default.
• W1759346585 cites W1979650150 @default.
• W1759346585 cites W2000744599 @default.
• W1759346585 cites W2002024027 @default.
• W1759346585 cites W2003269194 @default.
• W1759346585 cites W2009070322 @default.
• W1759346585 cites W2024651527 @default.
• W1759346585 cites W2029211332 @default.
• W1759346585 cites W2036193982 @default.
• W1759346585 cites W2047722872 @default.
• W1759346585 cites W2048125029 @default.
• W1759346585 cites W2053000230 @default.
• W1759346585 cites W2053466859 @default.
• W1759346585 cites W2077115476 @default.
• W1759346585 cites W2077447212 @default.
• W1759346585 cites W2096255289 @default.
• W1759346585 cites W2096563093 @default.
• W1759346585 cites W209992625 @default.
• W1759346585 cites W2105133745 @default.
• W1759346585 cites W2105141806 @default.
• W1759346585 cites W2105823903 @default.
• W1759346585 cites W2122010224 @default.
• W1759346585 cites W2130713902 @default.
• W1759346585 cites W2131581143 @default.
• W1759346585 cites W2132135347 @default.
• W1759346585 cites W2133325756 @default.
• W1759346585 cites W2141413316 @default.
• W1759346585 cites W2148706741 @default.
• W1759346585 cites W2161282723 @default.
• W1759346585 cites W2170344041 @default.
• W1759346585 cites W2170487286 @default.
• W1759346585 cites W2328060354 @default.
• W1759346585 cites W4239675078 @default.
• W1759346585 cites W4378103000 @default.
• W1759346585 doi "https://doi.org/10.1053/j.jvca.2015.10.010" @default.
• W1759346585 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/26774199" @default.
• W1759346585 hasPublicationYear "2016" @default.
• W1759346585 type Work @default.
• W1759346585 sameAs 1759346585 @default.
• W1759346585 citedByCount "28" @default.
• W1759346585 countsByYear W17593465852017 @default.
• W1759346585 countsByYear W17593465852018 @default.
• W1759346585 countsByYear W17593465852019 @default.
• W1759346585 countsByYear W17593465852020 @default.
• W1759346585 countsByYear W17593465852021 @default.
• W1759346585 countsByYear W17593465852022 @default.
• W1759346585 countsByYear W17593465852023 @default.
• W1759346585 crossrefType "journal-article" @default.
• W1759346585 hasAuthorship W1759346585A5008880626 @default.
• W1759346585 hasAuthorship W1759346585A5010118602 @default.
• W1759346585 hasAuthorship W1759346585A5024195170 @default.
• W1759346585 hasAuthorship W1759346585A5026359213 @default.
• W1759346585 hasAuthorship W1759346585A5041838652 @default.
• W1759346585 hasAuthorship W1759346585A5045866570 @default.
• W1759346585 hasAuthorship W1759346585A5066614622 @default.
• W1759346585 hasAuthorship W1759346585A5079047956 @default.
• W1759346585 hasConcept C126322002 @default.
• W1759346585 hasConcept C141071460 @default.
• W1759346585 hasConcept C159641895 @default.
• W1759346585 hasConcept C167135981 @default.
• W1759346585 hasConcept C2776376669 @default.
• W1759346585 hasConcept C2778789114 @default.
• W1759346585 hasConcept C2778881276 @default.
• W1759346585 hasConcept C2779412105 @default.
• W1759346585 hasConcept C2779978075 @default.
• W1759346585 hasConcept C2780073493 @default.
• W1759346585 hasConcept C2780472472 @default.
• W1759346585 hasConcept C42219234 @default.
• W1759346585 hasConcept C71924100 @default.
• W1759346585 hasConceptScore W1759346585C126322002 @default.
• W1759346585 hasConceptScore W1759346585C141071460 @default.
• W1759346585 hasConceptScore W1759346585C159641895 @default.
• W1759346585 hasConceptScore W1759346585C167135981 @default.
• W1759346585 hasConceptScore W1759346585C2776376669 @default.
• W1759346585 hasConceptScore W1759346585C2778789114 @default.
• W1759346585 hasConceptScore W1759346585C2778881276 @default.
• W1759346585 hasConceptScore W1759346585C2779412105 @default.
• W1759346585 hasConceptScore W1759346585C2779978075 @default.
• W1759346585 hasConceptScore W1759346585C2780073493 @default.
• W1759346585 hasConceptScore W1759346585C2780472472 @default.
• W1759346585 hasConceptScore W1759346585C42219234 @default.
• W1759346585 hasConceptScore W1759346585C71924100 @default.
• W1759346585 hasIssue "4" @default.

• next